BOLD logo

BOUNDLESS BIO INC

BOLDNASDAQ
🏆 #4240 by market capUS Equity
$2.53▲ $0.04 (+1.61%)
Latest quote
🔔
Track BOLD
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.6%
7d▲ 4.3%
14d▲ 7.0%
30d▼ 1.2%
ytd▲ 112.6%
1y▲ 73.3%
🏦Market Cap
$58M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.50 – $2.53
52-Week Range
$0.96 – $3.16
Volume (shares)
200
Avg Volume (shares)
—
Shares Outstanding
22.7M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-0.8
P/S Ratio
0.0x
EPS (TTM)
$-2.85
Dividend Yield
0.00%
Dilution (1yr)
+31.7%
BOLD logo

BOUNDLESS BIO INC

BOLD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$64M▼ −13.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$47M▼ −25.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
22.4M▲ +31.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$31M▼ −$10M YoY
StockOtter · stockotter.space

About BOUNDLESS BIO INC

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.